Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002
This article was originally published in The Gray Sheet
Executive Summary
Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review
You may also be interested in...
Liquid-Based Cytology Recommended For UK By NICE Appraisal Committee
A preliminary recommendation in favor of liquid-based cytology (LBC) adoption in the UK reverses a June 2000 National Institute for Clinical Excellence (NICE) guidance which concluded that data were insufficient to support nationwide use
Liquid-Based Cytology Recommended For UK By NICE Appraisal Committee
A preliminary recommendation in favor of liquid-based cytology (LBC) adoption in the UK reverses a June 2000 National Institute for Clinical Excellence (NICE) guidance which concluded that data were insufficient to support nationwide use
Digene DNA Pap Approval Anticipation Boosts Stock 45% In February
Investor expectations for imminent approval of Digene's HPV DNA Pap test as a primary screen for cervical cancer appeared to drive a 44.6% increase in the company's stock price to $16.59 in February